Envisagenics Appoints Sudhir Rao as Chief Business Officer

Envisagenics strengthens its leadership team with the appointment of Sudhir Rao as Chief Business Officer, aiming to enhance its position in RNA splicing therapeutics.

Envisagenics, an AI-driven biotechnology company focused on RNA splicing research and therapeutics, has announced the appointment of Sudhir Rao as Chief Business Officer (CBO). This strategic move aims to bolster the company's leadership team and drive its growth in the field of RNA splicing therapeutics.

Sudhir Rao brings over 30 years of experience in the life sciences industry, with a strong background in biopharma R&D, business development, and alliance management. His previous roles include Senior Vice President/Head of Business Development at Expansion Therapeutics and Vice President of Business Development at Genocea Biosciences. Rao's expertise in forming high-impact partnerships across various therapeutic areas will be instrumental in advancing Envisagenics' mission.

Envisagenics' CEO, Maria Luisa Pineda, expressed enthusiasm about Rao's appointment, highlighting his extensive experience and passion for innovative science as key assets for the company. Rao himself is eager to contribute to Envisagenics' development, particularly through the company's AI-driven SpliceCore platform, which identifies novel targets for treatments in oncology and neurodegenerative diseases.

Founded in 2014, Envisagenics collaborates with biopharmaceutical companies and academic institutions to enhance drug discovery capabilities. The company has previously partnered with organizations such as the Lung Cancer Initiative at Johnson & Johnson, Biogen, and BMS.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish. For example, in the Daily AI Brief you can read the most up to date AI news round-up 6 days per week.

Also, consider following our LinkedIn page AI Brief.

Subscribe to Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates

You May Also Like